Genuone Sciences has challenged the unlisted patents of Trajenta (linagliptin).

Industry interpretations are that the move is the company’s strategy to remove uncertainties in releasing generic versions of Trajenta and to additionally attract CMO deals”

According to industry sources on the 24th, Genuone Sciences filed a trial to confirm the passive scope of patent rights and invalidation trials for the 5 Trajenta patents, 3 of which are use patents set to expire in May 2027, and one substance and one process patent set to expire in April 2027.

One interesting thing to note is that all these patents are not listed on Korea’s patent register. As the patents are not list